H I Scher|T A Splinter - JoVE Visualize

Showing results (171-180 of 263) with videos related to

Pageof 27

Sort By:

Anti-Cancer Drugs|July 19, 2001

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagusM B Polee, T C Kok, P D Siersema, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1991

Radioiodinated somatostatin analog scintigraphy in small-cell lung cancerD J Kwekkeboom, E P Krenning, W H Bakker, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1992

A phase I study of local treatment of liver metastases with recombinant tumour necrosis factorG P van der Schelling, J N IJzermans, T C Kok, et al.

Prostate Cancer and Prostatic Diseases|March 5, 2004

Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapyD E Orange, M Jegathesan, N E Blachère, et al.

Prostate Cancer and Prostatic Diseases|March 19, 2014

Androgen dynamics and serum PSA in patients treated with abiraterone acetateC J Ryan, W Peng, T Kheoh, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997

Bicalutamide for advanced prostate cancer: the natural versus treated history of diseaseH I Scher, C Liebertz, W K Kelly, et al.

The Journal of Urology|April 1, 1987

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladderG Stoter, T A Splinter, J A Child, et al.

Therapeutic Drug Monitoring|January 1, 1986

Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)J B Vermorken, W J van der Vijgh, I Klein, et al.

Cancer Research|October 16, 1999

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft modelsD B Agus, H I Scher, B Higgins, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000

Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivoF M Sirotnak, H G Wendel, W G Bornmann, et al.

Pageof 27

Showing results (171-180 of 263) with videos related to

Sort By:

Pageof 27

Anti-Cancer Drugs|July 19, 2001

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagusM B Polee, T C Kok, P D Siersema, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1991

Radioiodinated somatostatin analog scintigraphy in small-cell lung cancerD J Kwekkeboom, E P Krenning, W H Bakker, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1992

A phase I study of local treatment of liver metastases with recombinant tumour necrosis factorG P van der Schelling, J N IJzermans, T C Kok, et al.

Prostate Cancer and Prostatic Diseases|March 5, 2004

Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapyD E Orange, M Jegathesan, N E Blachère, et al.

Prostate Cancer and Prostatic Diseases|March 19, 2014

Androgen dynamics and serum PSA in patients treated with abiraterone acetateC J Ryan, W Peng, T Kheoh, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997

Bicalutamide for advanced prostate cancer: the natural versus treated history of diseaseH I Scher, C Liebertz, W K Kelly, et al.

The Journal of Urology|April 1, 1987

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladderG Stoter, T A Splinter, J A Child, et al.

Therapeutic Drug Monitoring|January 1, 1986

Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)J B Vermorken, W J van der Vijgh, I Klein, et al.

Cancer Research|October 16, 1999

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft modelsD B Agus, H I Scher, B Higgins, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000

Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivoF M Sirotnak, H G Wendel, W G Bornmann, et al.

Pageof 27